{
    "symbol": "EYEN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-12 22:37:07",
    "content": " We are assuming a six-month review period and are making plans for a targeted commercial launch, if approved, for the first half of next year. We are assuming a six-month review period and are making plans for a targeted commercial launch, if approved, for the first half of next year. So, while we are eager to successfully complete VISION-2 and submit an NDA for MicroLine, we remain nonetheless confident that we will be able to capture a significant share of the market irrespective of the number of therapeutic options that may ultimately exist due to the many unique advantages conferred to the user by the Optejet dispenser."
}